Golden
Venomyx Therapeutics

Venomyx Therapeutics

Venomyx Therapeutics is a biotechnology company producing recombinant antivenom.

Venomyx Therapeutics is a privately held biotech company based in La Jolla, California. The company is focused on producing a recombinant antivenom that will make treatment safer, more effective, portable and affordable for snakebite victims. 



Venomyx's lead product candidate, Vipax is aimed to be a broad spectrum antivenom that works for all medically relevant species. It will release four iterations of Vipax for the regions of Asia, Africa, South America, and the U.S. It also is meant to be safe, with low or no side effects, and portable (similar to an EpiPen). The company aims to manufacture its product at scale using microbial fermentation. 



The company is also applying its technology to develop novel bacterial anti-toxins. It is targeting antibiotic resistant strains, such as MRSA, as well as those of interest to biodefense, such as Anthrax. The technology aims to target the toxin secreted by bacteria, thereby circumventing antibiotic resistance.

Timeline

People

Name
Role
Related Golden topics

Alysia Silberg

Investor



Blake Ilstrup

Attorney



Christian Meyers

Investor



Daniel T. Dempsey

Founder & CEO



Deepankar Roy

Co-Founder & COO



Mads Riegel

Director of Business Development



Phil Tan

Director of Scientific Research



William Hayes

Employee



Further reading

Title
Author
Link
Type

An Interview With Daniel Dempsey of Venomyx Therapeutics - IndieBio



Web

Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References